SGS Enrolls First Patient into Biophytis’ COVA Clinical Study, a COVID-19 Clinical Trial
SGS is pleased to announce the enrolment of the first patient into an important new clinical trial designed to examine the safety, tolerability, and efficacy of a potential drug candidate for people suffering with COVID-19 related respiratory failure.
SGS was chosen by French biotech company Biophytis to conduct its COVA study – a Clinical Trial with Sarconeos (BIO101) for the Treatment of Patients with COVID-19 Related Respiratory Failure. The study, which has so-far received regulatory approval in Belgium, France, Brazil, the UK, and US, will initially recruit around 50 patients who have tested positive for COVID-19 and have also developed severe respiratory symptoms in the previous seven days. They must have obvious COVID-19 symptoms – e.g. pneumonia and oxygen distress – but cannot have been reliant on high-flow oxygen use or assisted ventilation during the previous 28-days.
Steven Thys, SGS’s Director of Global Clinical Operations commented: “As the whole world faces up to the challenge of finding effective treatments for COVID-19 we are pleased to announce the first patient has been successfully enrolled into the COVA Study. In the coming weeks, we may see more patients entering the study as more sites from different countries will join the study.
“Biophytis’ decision to choose SGS as its partner in the COVA Study is testament to our considerable expertise as a contract research organization with proficiency in the field of infectious diseases. Together, we have worked intensively to set up this study in a remarkably efficient timeframe.”
At the end of this initial 28-day trial, an Independent Data Monitoring Committee (IDMC) will conduct an interim analysis to determine whether the study should progress. The second phase could involve the recruitment of a further 260 patients. Totaling 310 patients participating in the trial.
About SGS Clinical Research Services
SGS Clinical Research is a leading contract research organization (CRO) with over 35 years of experience in clinical research and bioanalytical testing. Able to offer phase I to IV clinical trials, they have considerable experience with infectious diseases, respiratory disease, and vaccines.
SGS Clinical Research supports leading biotech and pharmaceutical companies in the design and conduct of clinical studies. By leveraging its global network of experts and clinical trial centers, SGS can optimize timelines and support study submissions, all in accordance with regulatory conditions.
For further information, please contact:
Director, Global Clinical Operations, SGS
t: +32 15 27 32 45
About Biophytis SA
Biophytis SA is a clinical-stage biotechnology company specialized in the development of drug candidates to slow down degenerative processes and improve functional abilities in patients with age-related diseases, especially neuromuscular diseases.
SGS is the world’s leading inspection, verification, testing and certification company. We are recognized as the global benchmark for quality and integrity. With more than 89,000 employees, we operate a network of more than 2,600 offices and laboratories around the world.